Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A update
Dokumenttyp:
Meeting Abstract
Autor(en):
Arranz Arija, J. A.; Yu, E. Y.; Piulats, J. M.; Gravis, G.; Laguerre, B.; Oudard, S.; Fong, P. C.; Kolinsky, M. P.; Augustin, M.; Todenhofer, T.; Kam, A. E.; Gurney, H.; Tafreshi, A.; Retz, M.; Berry, W. R.; Mar, N.; Wu, H.; Qiu, P.; Schloss, C.; de Bono, J. S.